US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cypherpunk Technologies Inc.

2.75

+0.990056.25%

Post-market: 2.70-0.0503-1.83%19:59 EST

Volume:263.22M

Turnover:766.25M

Market Cap:155.79M

PE:-1.72

High:3.55

Open:2.06

Low:1.89

Close:1.76

52wk High:3.58

52wk Low:0.2223

Shares:56.65M

Float Shares:49.88M

Volume Ratio:1.59

T/O Rate:527.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6003

EPS(LYR):-1.8115

ROE:--

ROA:--

PB:--

PE(LYR):-1.52

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Cypherpunk Technologies Inc.

Exchange:

NASDAQ

Establishment Date:

2011

Employees:

52

Office Location:

47 Thorndike Street,Suite B1-1,Cambridge,Massachusetts,United States

Website:

http://www.leaptx.com

Zip Code:

02141

Phone:

Fax:

- -

Introduction:

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Directors

Name

Position

Douglas E. Onsi

Director,Chief Executive Officer and President

Khing Oei

Director and Non-Executive Chairman

Thomas Dietz

Lead Independent Director

William McEvoy

Director and Chief Investment Officer

Christian Richard

Director

Christopher K. Mirabelli

Director

James Cavanaugh

Director

Joseph Loscalzo

Director

Nissim Mashiach

Director

Patricia Martin

Director

Richard Schilsky

Director

William Li

Director

Shareholders

Name

Position

Douglas E. Onsi

Director,Chief Executive Officer and President

Christine Granfield

Vice President, Head of Regulatory Affairs and Quality

Jason Baum

Chief Scientific Officer

Mark O'Mahony

Chief Manufacturing Officer

William McEvoy

Director and Chief Investment Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYPH/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYPH\",,,,,undefined,":{"symbol":"CYPH","market":"US","secType":"STK","nameCN":"Cypherpunk Technologies Inc.","latestPrice":2.75,"timestamp":1763154000000,"preClose":1.76,"halted":0,"volume":263218687,"hourTrading":{"tag":"盘后","latestPrice":2.6997,"preClose":2.75,"latestTime":"19:59 EST","volume":3543392,"amount":9502570.0282,"timestamp":1763168399545},"delay":0,"floatShares":49877123,"shares":56651840,"eps":-1.600252,"marketStatus":"Market Closed","change":0.99,"latestTime":"11-14 16:00:00 EST","open":2.06,"high":3.55,"low":1.8901,"amount":766250681.6738287,"amplitude":0.943125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.600252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1763370000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.76,"preHourTrading":{"tag":"盘前","latestPrice":2.0698,"preClose":1.76,"latestTime":"09:29 EST","volume":6354910,"amount":13097256.620515,"timestamp":1763130594895},"postHourTrading":{"tag":"盘后","latestPrice":2.6997,"preClose":2.75,"latestTime":"19:59 EST","volume":3543392,"amount":9502570.0282,"timestamp":1763168399545},"volumeRatio":1.5885906267835666,"impliedVol":2.985,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYPH\",,,,,undefined,":{"symbol":"CYPH","floatShares":49877123,"roa":"--","roe":"--","lyrEps":-1.811498,"volumeRatio":1.5885906267835666,"shares":56651840,"dividePrice":0,"high":3.55,"amplitude":0.943125,"preClose":1.76,"low":1.8901,"week52Low":0.2223,"pbRate":"--","week52High":3.58,"institutionHeld":0,"latestPrice":2.75,"eps":-1.600252,"divideRate":0,"volume":263218687,"delay":0,"ttmEps":-1.600252,"open":2.06,"prevYearClose":2.875,"prevWeekClose":0.4583,"prevMonthClose":0.4472,"prevQuarterClose":0.454,"fiveDayClose":0.4583,"twentyDayClose":0.5515,"sixtyDayClose":0.275},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"CYPH","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2025-08-14","symbol":"CYPH","fiscalQuarterEnding":"2025/06","expectedEps":-0.29,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.4},{"market":"US","date":"2025-05-13","symbol":"CYPH","fiscalQuarterEnding":"2025/03","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2025-03-26","symbol":"CYPH","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742961600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2024-11-13","symbol":"CYPH","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.44}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYPH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1738386000000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":118044172,"yearFounded":2011,"employeeNum":52,"address":"47 Thorndike Street,Suite B1-1,Cambridge,Massachusetts,United States","zipCode":"02141","officePhone":"617 714 0360"},"stockCompanyDetail":{"websiteUrl":"http://www.leaptx.com","stockEarnings":[{"period":"1week","weight":5.0004},{"period":"1month","weight":3.4071},{"period":"3month","weight":9.2574},{"period":"6month","weight":5.8579},{"period":"1year","weight":-0.0484},{"period":"ytd","weight":-0.0435}],"compareEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1308},{"period":"1year","weight":0.1324},{"period":"ytd","weight":0.1465}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.027306},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021879},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.077902},{"month":4,"riseRate":0.444444,"avgChangeRate":0.024066},{"month":5,"riseRate":0.333333,"avgChangeRate":0.10817},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.10012},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.017339},{"month":8,"riseRate":0.333333,"avgChangeRate":0.008005},{"month":9,"riseRate":0.444444,"avgChangeRate":0.109211},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.026459},{"month":11,"riseRate":0.333333,"avgChangeRate":0.497517},{"month":12,"riseRate":0.5,"avgChangeRate":0.157619}],"exchange":"NASDAQ","name":"Cypherpunk Technologies Inc.","nameEN":"Cypherpunk Technologies Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CYPH\",market:\"US\",,,undefined,":{"directors":[{"name":"Douglas E. Onsi","position":"Director,Chief Executive Officer and President"},{"name":"Khing Oei","position":"Director and Non-Executive Chairman"},{"name":"Thomas Dietz","position":"Lead Independent Director"},{"name":"William McEvoy","position":"Director and Chief Investment Officer"},{"name":"Christian Richard","position":"Director"},{"name":"Christopher K. Mirabelli","position":"Director"},{"name":"James Cavanaugh","position":"Director"},{"name":"Joseph Loscalzo","position":"Director"},{"name":"Nissim Mashiach","position":"Director"},{"name":"Patricia Martin","position":"Director"},{"name":"Richard Schilsky","position":"Director"},{"name":"William Li","position":"Director"}],"executives":[{"name":"Douglas E. Onsi","position":"Director,Chief Executive Officer and President"},{"name":"Christine Granfield","position":"Vice President, Head of Regulatory Affairs and Quality"},{"name":"Jason Baum","position":"Chief Scientific Officer"},{"name":"Mark O'Mahony","position":"Chief Manufacturing Officer"},{"name":"William McEvoy","position":"Director and Chief Investment Officer"}]}}}